Despite multiple anti-VEGF medications that are now in clinical development or have already been approved, their impact on lung cancer outcomes has been limited, with only minor improvements observed compared to the encouraging preclinical results [5,6]. The gene discussed is VEGFA; the disease is lung cancer.